Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128070 | 1.00 | ATM (0.37) | ATMACEKMT2AMAPK1TDP1 | |
| SCHEMBL23677371 | 1.00 | ATM (0.37) | ATMACEKMT2AMAPK1TDP1 | |
| SCHEMBL18204645 | 0.86 | ATM (0.34) | ATM | |
| SCHEMBL26009605 | 0.79 | ACE (0.34) | ATMACEKMT2AMAPK1 | |
| SCHEMBL18212793 | 0.78 | MAPK1 (0.33) | ATMACEKMT2AMAPK1 | |
| SCHEMBL23677350 | 0.78 | MAPK1 (0.33) | ATMACEKMT2AMAPK1 | |
| SCHEMBL19588833 | 0.78 | MAPK1 (0.33) | ATMACEKMT2AMAPK1 | |
| SCHEMBL11571970 | 0.77 | ENO1 (0.34) | ATMKMT2AMAPK1 | |
| SCHEMBL23677586 | 0.75 | ACE (0.32) | ATMACEKMT2A | |
| SCHEMBL31694877 | 0.75 | ACE (0.32) | ATMACEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292101-B1 | TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3292101-B1 | TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107709295-B | Tricyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-08 | — | — | US | disclosed |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3292101-A1 | TRICYCLIC SULFONES AS ROR MODULATORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2016179460-A1 | TRICYCLIC SULFONES AS RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | ATM 4833/4885ACE 3654/4885KMT2A 2708/4885 |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | ATM 4831/4885ACE 3717/4885KMT2A 3366/4885 |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | RORB, RORC, RORA | ATM 4859/4885ACE 3919/4885KMT2A 2782/4885 |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | ATM 4833/4885ACE 3654/4885KMT2A 2708/4885 |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | ATM 4831/4885ACE 3717/4885KMT2A 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.